eart failure (HF) is a major and growing public health problem in developed countries. 1 In the United States, approximately 5 million individuals have HF, and more than 550,000 new cases are diagnosed annually. 1 To our knowledge, only a few reports have focused on this issue in Japan. 2, 3 The purpose of this study was to estimate the impact of population aging on the number of outpatients with left ventricular dysfunction (LVD) over the next 5 decades in Japan. All study participants provided informed consent and the study design was approved by the ethics review board of Niigata University Graduate School of Medical and Dental sciences.
(see Appendix 1) .
The ratio of outpatients with SD or IDD to the general population of Sado City in 2003 was calculated as follows: 4, 5 The 2005 census indicated the distribution of age groups in Japan. 6 The proportions of 3 major age groups (children (aged under 15), working-age (15-64) and aged (aged ≥65) in the total population were 14%, 66%, and 20%, respectively, in Japan, and 12%, 53%, and 35%, respectively, in Sado City. The ratio of men to women aged 45 and over was 1:1.15 in Japan and 1:1.20 in Sado City.
The second data source was the population projections of the Report of the Japanese National Institute of Population and Social Security Research (2006) for the next 5 decades. 7 The projected numbers of Japanese patients were calculated by multiplying each ratio by the projected count of its corresponding population category.
The total count of Japanese outpatients with LVD was 979,000 in 2005 and is expected to increase rapidly by 90,000 every 5 years until 2020, then gradually by 24,000 every 5 years until 2035, peaking at 1.32 million LVD patients in 2035. Males will dominate the LVD population as a whole, and in particular those aged <85 years. On the other hand, LVD patients aged ≥85 years will show female predominance, and the total count of this category will increase rapidly from 91,000 in 2005 to 333,000 in 2040. The epidemic will persist in the decremental phase of the Japanese population after 2005. The total count of Japanese LVD patients aged 65-84 years will gradually increase to a peak by 2025, followed by a later reduction, whereas the count of LVD patients aged <65 years has already been decreasing since 2005.
Thus, the estimated total count of outpatients with LVD in Japan was 979,000 in 2005, according to the calculations Background The future burden of heart failure in Japan was projected to 2055 in order to prospectively estimate of the number of these patients.
Methods and Results
The statistics are based on prevalence data of left ventricular dysfunction (LVD) in Sado City using the Sado Heart Failure Study (2003) of this study. In another study, the number of Japanese patients with chronic HF was estimated by indirect methods, such as the frequency of digitalis prescription, 3 and was found to be 1.07 million, consistent with our estimate. However, these estimates are much lower than the US ones. 1 Considering that the population of the US is 2.5-fold that of Japan, the total count of LVD patients in Japan is expected to be less than half that of the US. Nevertheless, exact comparisons of the LVD patient counts between Japan and the US seem difficult because of the use of different methodologies and population structures. However, the incidence of myocardial infarction in Japan is reported to be onesixth that of the US. 8 Therefore, the lower number of LVD patients in Japan could be partly explained by the lower prevalence of ischemic heart disease.
The incidence of LVD will first rapidly and then gradually increase to a peak of 1.32 million patients by 2035, with rapid acceleration occurring by 2020. As the proportion of LVD cases in the general population increases progressively with age, the problem of LVD is expected to inflate in progressively aging communities such as Japan (currently, 1 in 5 Japanese is aged over 65 years, and this proportion will reach 1 in 4 by 2020, and 1 in 3 by 2050 7 ). The impact of LVD in Japan is greater than in European countries, because a larger proportion of Japan's current population is older; to reach a similar increase in the general aging population would require 115 years for France and 88 years for Sweden. 9 In particular, the epidemic-like prevalence of LVD patients aged ≥85 years in Japan will be unprecedented in the world. This category will increase rapidly (in 1,000 s) of SD, IDD, LVD, and from 91,000 in 2005, to 333,000 in 2040 and the epidemic will be sustained until 2045. This is in contrast to a gradual reduction in the number of LVD patients aged <65 from 2005, and those aged 65-84 years after 2025. In this setting, it is important to confirm that the unique age structure of the general population in Japan requires the application of evidence-based algorithms derived from longitudinal and observational cohort studies conducted in Japanese populations. Limitations of this study include, first, that the Japanese LVD prevalence data were derived from hospital-based studies. In fact, these estimates reflect the number of outpatients who are confirmed by echocardiography to have LVD in community hospitals, not in the general population. Thus, there is a possibility of underestimating the actual prevalence of LVD in the general population because of selection bias arising from the fact that patients with latent LVD in the community are not identified simply because of their non-referral to echocardiographic examination. Second, Sado City is an isolated island with an advanced aging population, and may not be a representative Japanese community model. However, no one representative city has been proposed as a standard to study the prevalence of LVD in Japan until now; thus, Sado City is the nearest to realizing this goal owing to its natural isolation, suitable population size, and identifiable, easily accessible organized centers for medical care. Third, this future projection was undertaken on the assumption that the prevalence of LVD in 2003 would remain constant in the future in Japan. Actually, the incidence of LVD can change. Therefore, recalibrating the prevalence over the short term seems prudent for a more precise projection of long-term LVD prevalence.
In conclusion, as the proportion of LVD patients in Japan increases progressively with age, it is expected to simulate a future epidemic.
